Linerixibat Long-term Safety, and Tolerability Study
Status:
Recruiting
Trial end date:
2025-12-23
Target enrollment:
Participant gender:
Summary
This is an open-label, non-comparator, global, multi-center, long-term safety study for
evaluating safety and tolerability of linerixibat in participants with cholestatic pruritus
in primary biliary cholangitis (PBC) who participated in a prior clinical trial with
linerixibat (BAT117123 [NCT01899703], 201000 GLIMMER [NCT02966834] (group 1) or 212620
GLISTEN [NCT00210418]) (group 2). All participants will receive open-label linerixibat for
the duration of the study. The duration of the study will be approximately four years until
study end, however the total duration of study participation will vary by participant
depending upon time of entry relative to study end in their respective country.